MarketPulse

central nervous system disorders

3 articles
BenzingaBenzinga··Benzinga

NBTX Denies Acquisition Speculation, Refutes Media Claims

Nanobiotix denies acquisition speculation, stating no acquisition intent or assessment underway. Company cites factual inaccuracies in media reports.
NBTXbiotechnologyoncology
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling Praxis Stock Soars 700% as Major Fund Doubles Down With $266M Bet

Deerfield Management boosts $PRAX stake to $266M as biotech stock surges 685% annually. Company eyes $20B+ pipeline revenue potential with two FDA applications pending.
PRAXFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment